Protozoa infectious disease

Researchers in Gabon are testing whether a tea made from dried Artemisia annua leaves can clear malaria parasites in adults who carry the infection without feeling sick. The trial enrolls 20 semi-immune adults aged 18 to 45 who have low levels of Plasmodium falciparum in their bl…

This Phase 2b trial tests whether a new drug, SJ733, combined with tafenoquine can cure P. vivax malaria and prevent it from returning. About 104 adults with uncomplicated malaria will receive different schedules of SJ733 plus tafenoquine, or standard chloroquine plus tafenoquine…

This study tests two doses of an experimental oral drug, LXE408, against a standard treatment (miltefosine) for localized cutaneous leishmaniasis, a parasitic skin disease. About 250 adults in the Americas will take the medicine for several weeks. The main goal is to see if the s…

This study tests a shorter, higher-dose course of primaquine to cure vivax malaria and prevent it from coming back. Current treatments take too long, so a 3-day course could make it easier for patients to complete therapy. The trial involves over 1,000 people aged 5 and older wit…

Researchers are testing three experimental malaria vaccines (LYB014, LYB017, and LYB027) in healthy adults aged 18 to 50. Participants receive either a low or high dose of one vaccine combined with an immune-boosting adjuvant, or the adjuvant alone as a comparison. The trial trac…

This study tests whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in 375 adults and adolescents aged 14 to 60. Participants will receive either the standard dose or a half-dose, and researchers will measure their immune response and safety.…

This trial tests a new malaria vaccine, PfSPZ-LARC2, made from live but genetically weakened malaria parasites that stop developing in the liver and never reach the bloodstream. The goal is to see if a single dose can safely and effectively protect healthy adults in Burkina Faso …

This phase II trial tests a new malaria vaccine called PvRII/Matrix-M in 36 healthy Thai adults aged 20-55. Half receive the vaccine, half a placebo. After three doses, 24 volunteers will be exposed to the malaria parasite in a controlled setting to see if the vaccine reduces inf…

This study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes…

This early-stage trial is testing a new vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria, to check if it is safe and whether it triggers an immune…

This study tests a specially formulated dispersible tablet, Coartem Baby, in infants weighing between 2 and 5 kg who have uncomplicated malaria. The goal is to see if the drug is safe and effectively clears symptoms like fever and chills. Twenty infants will receive the standard …

This phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work …

This study tests if a 3-day medicine called nitazoxanide can treat Cryptosporidium infection in 480 malnourished children aged 6-12 months in Bangladesh. The goal is to shorten diarrhea and clear the parasite from stool. Half the children get the medicine, half get a placebo, and…

This study tests whether adding a fractional CO₂ laser to standard Glucantime injections helps heal skin sores from leishmaniasis faster and with less scarring. About 150 adults will be randomly assigned to get either the injection alone or the injection plus laser. Researchers w…

This study tests whether combining tafenoquine with different antimalarial drugs can better prevent P. vivax malaria from coming back. About 300 adults in Thailand with uncomplicated P. vivax infection will receive one of three drug pairs and be monitored for 6 months. The goal i…

This study looks at how much of the malaria drugs primaquine and tafenoquine pass to babies through breast milk. It involves 60 breastfeeding mothers in Papua New Guinea who recently gave birth. The goal is to find a safe way to treat and prevent relapses of vivax malaria in new …

This study looks at whether a malaria drug called tafenoquine interacts with two other common malaria treatments (DHA-piperaquine and artesunate-pyronaridine) in adults with vivax malaria. About 507 participants will receive one of the combinations or a delayed treatment to compa…

This Phase 3 trial in Ethiopia will compare four different drug regimens against the standard treatment for cutaneous leishmaniasis, a parasitic skin disease. 900 patients aged 4 to 65 will be hospitalized and treated for up to 28 days, with follow-up for 6 months. The goal is to…

This study will test the safety and effectiveness of a drug called tafenoquine in 60 children with vivax malaria in Papua New Guinea. Vivax malaria can hide in the liver and come back, so the goal is to find a treatment that clears the infection completely. The children will rece…

This early study tests a gel made with the drug miltefosine for people with uncomplicated cutaneous leishmaniasis, a skin infection from a parasite. Fifteen adults will apply the gel to their sores daily for 28 days. The main goal is to see if the gel is safe and if it helps the …

This early-stage study tests whether wearable biosensors (like a wristband or earphones) can detect malaria infection before symptoms appear. 32 healthy adults will be exposed to the malaria parasite or a placebo in a controlled setting. Researchers will compare biosensor reading…

This study tests whether a mobile app using artificial intelligence can help frontline health workers in sub-Saharan Africa better diagnose skin-related neglected tropical diseases, like leprosy and scabies. Researchers will collect images from dermatologists to train the AI, the…

This study tests whether giving malaria medicine to school-age children can lower malaria cases in the entire community. School children often carry the malaria parasite without symptoms and spread it to others. The trial will involve about 4,800 children in The Gambia and measur…

This trial tests whether giving schoolchildren in Kenya an antimalarial drug every month, instead of every three months, better protects their brain function and school performance. Researchers will enroll 1,500 children aged 6 to 10 from six primary schools. Half will receive mo…

This trial tests whether baby wraps (called lesus) treated with long-lasting insecticide can protect young children from malaria. About 1,300 mothers and their infants (2-4 months old) will be randomly assigned to receive a wrap treated with permethrin, etofenprox, or an untreate…

This trial tests whether a single oral dose of lotilaner, a drug currently used in animals, can make human blood lethal to Anopheles gambiae mosquitoes, the main carriers of malaria. Healthy adults in Mali will receive either a low or high dose of lotilaner or a placebo, with or …

This study tests whether a device called the Guardian spatial emanator, which releases mosquito-repelling ingredients into the air, can be effectively added to an existing program that distributes antibiotics to children in Niger. The goal is to see if this integrated approach ca…

This early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe …

This study tests a new long-acting injection called MMV371 to see if it is safe and can prevent malaria. About 80 healthy people aged 12 to 50 in Rwanda will get either the study drug or a placebo. Researchers will check if the injection protects against malaria and monitor side …

This study tests new devices called LASER that release a chemical to repel mosquitoes, comparing them to indoor insecticide spraying and standard prevention (bed nets, vaccines). About 22,800 people in 69 Kenyan villages will take part over two years. Researchers will check malar…

This study in Uganda will test whether giving children both the R21 malaria vaccine and two different malaria prevention medicines works better than the vaccine alone. About 1,290 children will take part. The goal is to see if the combination can reduce malaria cases more effecti…

Researchers are measuring how often five animal-borne infections appear among inmates at the French Guiana Correctional Facility. The study follows newly arrived adults for up to 12 months, testing for Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis. The…

This early-stage trial will give 24 healthy adults three different malaria drugs—piperaquine, pyronaridine, and artesunate—alone and together to see how they interact. Researchers will measure drug levels in the blood and watch for side effects. The goal is to learn about safety …

This study follows 50 pregnant women with Chagas disease who take or have taken nifurtimox, to see if the drug causes harm to the baby or mother. Researchers will track birth defects, pregnancy outcomes, and infant health up to 12 months old. The goal is to collect safety data, n…

This study looks at whether giving unnecessary antibiotics to malnourished infants with diarrhea harms their immune system's ability to fight future infections. Researchers will compare two groups of 150 Bangladeshi infants: one group receives only supportive care, while the othe…

This study looks at how different genetic makeups affect the way healthy adults process the malaria prevention drug tafenoquine (ARAKODA). Researchers will measure drug levels in blood and urine over time, along with safety checks. The goal is to better understand how to dose the…

This study looks at whether giving iron to babies with low iron helps their bodies respond better to malaria and measles vaccines. About 324 infants in Kenya will take part. The goal is to see if treating iron deficiency can improve how well the vaccines protect them.